Overview
Sphere Bio provides picodroplet microfluidic instruments, consumables, and reagents for high-throughput single cell analysis, isolation, and monoclonality assurance. Their flagship Cyto-Mine Chroma platform screens up to 40 million cells per day for applications in antibody discovery, cell line development, cell therapy, and synthetic biology. As a Fluidic Sciences brand, they support biopharma R&D with integrated workflows for rapid screening of viable, high-producing clones.
Frequently asked questions
- What are Sphere Bio's key technologies and capabilities?
- Sphere Bio offers picodroplet microfluidic systems like Cyto-Mine Chroma for high-throughput single cell screening, analysis, isolation, imaging, and dispensing. These enable rapid assessment of productivity, viability, and monoclonality in applications such as antibody discovery and cell therapy.
- What applications do Sphere Bio's products support?
- Products support biopharmaceutical discovery, cell line development, cell therapy engineering, bioproduction, synthetic biology, and vaccine generation, screening up to 40 million cells per day.
- Where is Sphere Bio based and how to contact them?
- Sphere Bio is based in Cambridge, England. Contact Dr. Claire Cox at [email protected] or +44 (0)7365 209 441 for inquiries.